secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001193125-25-144204
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics Appoints Charles Schoch as Permanent CFO, Effective June 20, 2025
--------------------------------------------------------------------------------

- Charles Schoch, interim CFO since Jan 2024, promoted to permanent CFO; base salary increased to $440,000, target bonus 40%.
- Granted option to purchase 50,000 shares; 25% vests at one year, then ratably over 36 months.
- Schoch previously served as VP Finance and Corporate Controller; led capital raise of ~$86M in Q4 2024.
- Press release highlights upcoming BLA submission for CAN-2409 in localized prostate cancer.
- No family relationships or arrangements with other parties disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312525144204/0001193125-25-144204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312525144204/d915163d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-144204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer